Incyte Plummets After Cancer Drug Helps Fewer Than Expected
- Company's study contrasts with earlier released abstract
- Incyte's experimental therapy is paired with Merck's Keytruda
This article is for subscribers only.
Incyte Corp. shares fell the most in more than three years after the company said its combination drug for some forms of cancer helped patients less often in an early trial than related data had indicated.
Incyte said a smaller percentage of cancer patients responded to its combination therapy than it had reported earlier this week when looking at a smaller sample size. The combination drug includes Merck & Co.’s Keytruda paired with Incyte’s Epacadostat. The data was presented at the Society for Immunotherapy of Cancer meeting in National Harbor, Maryland.